Written and maintained by CASRAI Editorial Board
Last updated
Meso Scale Discovery (MSD) is a multiplex immunoassay platform from Meso Scale Diagnostics, LLC. It detects proteins with electrochemiluminescence (ECL) on plates that carry several capture spots per well, so one small sample can be measured for multiple analytes at once. This guide is for bench scientists and graduate researchers deciding whether the platform fits an assay, and it leans on one independent, peer-reviewed validation rather than vendor marketing.
What is Meso Scale Discovery?
MSD describes its approach as MULTI-ARRAY technology, which “combines electrochemiluminescence and arrays.” ECL is applied to MULTI-SPOT plates, and multi-spot panels measure multiple analytes simultaneously from a single, small-volume sample (MSD, Our Technology, read 2026-11-08). The company markets it as offering a combination of sensitivity, dynamic range and convenience; that is the vendor’s claim, and the independent data below are the better guide to real performance.
What is meant by “mesoscale”?
In this context, “Meso Scale” is simply the company’s name and brand: Meso Scale Diagnostics, LLC, and the MSD platform it sells. It is not a measurement unit or an assay type. (In other fields, such as meteorology, “mesoscale” separately means an intermediate spatial scale; the two uses are unrelated.)
How does Meso Scale Discovery work?
A published validation study (Bastarache et al., 2014) describes the MSD cytokine plates as a “specialized 96 well plate with integrated electrodes.” Capture antibodies sit in discrete spots within each well and bind the analyte. A detection antibody carrying an electrochemiluminescent label then binds, and the label is “only activated by an electric charge.” Because the label must be close to the electrode at the bottom of the plate to emit light, the authors note that this should in theory eliminate background interference (PMC4120713, read 2026-11-08).
Two practical consequences follow from that design. First, because each spot holds a different capture antibody, one well can report several analytes. Second, in the same study the multiplex assay used 25 µl per well for multiple analytes, while the singleplex ELISAs it was compared with required 100 µl per well for each analyte.
Panels reported in the validation study
| Kit (catalogue no.) | Analytes | Reported range |
|---|---|---|
| Human 7-plex (K15008C-1) | IFN-γ, IL-1β, IL-10, IL-12p70, IL-6, IL-8, TNF-α | 0.61–10,000 pg/ml |
| Mouse 7-plex (K15012C-1) | IFN-γ, IL-1β, IL-10, IL-12p70, IL-6, KC/GRO, TNF-α | 2.4–10,000 pg/ml |
Source: Bastarache et al., J Immunol Methods 2014;408:13–23. Other panels have different ranges.
What is the difference between MSD and ELISA?
An ELISA typically reads one analyte per well. MSD reads several analytes per well by light emitted at the electrode. The same study compared MSD multiplex kits with validated R&D Systems singleplex ELISAs for IL-6 and IL-8 in human samples, and for IL-6, KC and TNF-α in mouse samples. For a primer on the single-analyte format, see our guide to the sandwich ELISA assay.
| Measure | MSD multiplex | R&D singleplex ELISA |
|---|---|---|
| Sample volume | 25 µl/well, multiple analytes | 100 µl/well, per analyte |
| Human IL-6 intra-assay CV% | 3.49 | 2.03 |
| Human IL-8 intra-assay CV% | 2.04 | 6.12 |
| Human IL-6 lower limit of range | 0.61 pg/ml (7-plex) | 3.12 pg/ml |
| Mouse intra-assay CV% range | 9.5–28.5 | 4.3–23.7 |
Human IL-6 and IL-8 results correlated across the two platforms at R = 0.97. The authors concluded both approaches “compared favorably to well-validated singleplex ELISA’s”, and MSD detected IL-8 in samples where the R&D ELISA read below detection, which they attribute to higher sensitivity. Human spike-and-recovery on MSD averaged 103% (IL-6), 105% (IL-8) and 99% (TNF-α).
Where MSD performed less well
- The authors state the assay was “not as robust in mouse BAL and plasma samples” as in human plasma.
- Mouse TNF-α had a CV of 36.3%, and only 8 of 26 mouse plasma values fell within range.
- Spike recovery of R&D recombinant proteins on the MSD platform was lower: 45% (IL-6), 75% (IL-8) and 82% (TNF-α).
- Across all species and sample types, CV% was higher at low concentrations.
- Only the listed cytokines and matrices were tested, several mouse comparisons used small sample sizes (for example 4–7 samples), and sample-handling variables were not assessed.
MSD versus Luminex
The same paper cites earlier work (Chowdhury et al.) reporting that MSD had greater sensitivity while Luminex had improved precision at lower analyte concentrations, with both performing well at high concentrations. It also notes that, among platforms compared by Fu et al., the Bio-Plex and MSD performed best. That is a limited, secondhand comparison of specific kits; it does not rank the platforms in general.
How to decide whether MSD fits your assay
The study supports a few checks, each traceable to its findings rather than to a general rule:
- Validate per species and matrix. Performance in human plasma did not carry over to mouse bronchoalveolar lavage and plasma.
- Look at precision near your expected concentrations. CV% rose at low concentrations in every species and sample type tested.
- Run spike-and-recovery in your own matrix. Recovery varied by analyte (45% to 105% in the data above).
- Compare with a validated singleplex method on a subset of your samples before relying on multiplex values, as the authors did.
For a different approach to multiplexed protein measurement, see our guide to Olink and proximity extension assays. For multiplexing at the nucleic-acid level, see multiplexed PCR.
Who owns Meso Scale Discovery?
The platform is made by Meso Scale Diagnostics, LLC, of Rockville, Maryland. BioVeris Corporation’s annual report (Form 10-K filed 14 June 2005, SEC EDGAR, read 2026-11-08) states that MSD was a joint venture formed in 1995 by IGEN and Meso Scale Technologies, LLC (MST). BioVeris assumed IGEN’s interest in the merger that closed on 13 February 2004, and MST purchased BioVeris’s interests in MSD on 13 December 2004 under an August 2004 settlement. That filing predates today, so it describes the 2004 structure only and does not establish current ownership.
FAQ
What does MSD stand for?
In this context MSD refers to Meso Scale Discovery, the platform sold by Meso Scale Diagnostics, LLC.
Is MSD more sensitive than ELISA?
In the cited study, MSD had a lower range limit than the R&D ELISAs for human IL-6 and detected IL-8 where the ELISA was below detection. In mouse plasma most values were below detection and precision was weaker, so the answer depends on analyte, species and matrix.
How much sample does an MSD assay need?
The cited study used 25 µl per well for the multiplex panels versus 100 µl per well per analyte for singleplex ELISA. Other kits can differ.
Sources
- Bastarache JA, Koyama T, Wickersham NE, Ware LB. Validation of a multiplex electrochemiluminescent immunoassay platform in human and mouse samples. J Immunol Methods 2014;408:13–23. PMC4120713, read 2026-11-08.
- Meso Scale Diagnostics. Our Technology, read 2026-11-08.
- BioVeris Corp, Form 10-K filed 2005-06-14, SEC EDGAR, read 2026-11-08.
